Physician profile
Amber D Ball
NPI 1598345738
$613.47
in general payments reported to CMS, 2019-2025
14 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5.37 · 2022: $52.71 · 2023: $91.75 · 2024: $105 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $214.40 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $139.69 | 2023-2025 | |
| Lilly USA, LLC | $42.28 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $33.33 | 2022-2023 | Wegovy |
| Lundbeck LLC | $23.53 | 2024 | Vyepti |
| Baxter Healthcare | $23.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.44 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $20.31 | 2023 | Verquvo, Steglatro |
| Amgen INC. | $20.14 | 2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $20.00 | 2025 | Auvelity |
| Teleflex LLC | $19.97 | 2025 | Barrigel |
| Shield Therapeutics INC | $15.35 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.49 | 2022 | |
| Genentech USA, INC. | $5.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.